Endo-Lysosomal and Autophagy Pathway and Ubiquitin-Proteasome System in Mood Disorders: A Review Article
Petala Matutino Santos,Giovanna Pereira Campos,Camila Nascimento
DOI: https://doi.org/10.2147/NDT.S376380
IF: 2.989
2023-01-14
Neuropsychiatric Disease and Treatment
Abstract:Petala Matutino Santos, 1 Giovanna Pereira Campos, 1 Camila Nascimento 2 1 Center for Mathematics, Computing and Cognition (CMCC), Federal University of ABC (UFABC), São Paulo, Brazil; 2 Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil Correspondence: Camila Nascimento, Department of Psychiatry, University of São Paulo Medical School, 785, Doutor Ovídio Pires de Campos Street, São Paulo, SP, Brazil, Tel +55 11 2661 7928, Email Mood disorders are disabling conditions that cause significant functional impairment. Due to the clinical heterogeneity and complex nature of these disorders, diagnostic and treatment strategies face challenges. The etiology of mood disorders is multifactorial, involving genetic and environmental aspects that are associated with specific biological pathways including inflammation, oxidative stress, and neuroprotection. Alterations in these pathways may reduce the cell's ability to recover from stress conditions occurring during mood episodes. The endo-lysosomal and autophagy pathway (ELAP) and the ubiquitin-proteasome system (UPS) play critical roles in protein homeostasis, impacting neuroplasticity and neurodevelopment. Thus, emerging evidence has suggested a role for these pathways in mental disorders. In the case of neurodegenerative diseases (NDDs), a deeper understanding in the role of ELAP and UPS has been critical to discover new treatment targets. Since it is suggested that NDDs and mood disorders share clinical symptomatology and risk factors, it has been hypothesized that there might be common underlying molecular pathways. Here, we review the importance of the ELAP and UPS for the central nervous system and for mood disorders. Finally, we discuss potential translational strategies for the diagnosis and treatment of major depressive disorder and bipolar disorder associated with these pathways. Keywords: mood disorders, endo-lysosomal pathway, ubiquitin-proteasome system, autophagy, endo-lysosome, neuroplasticity, novel treatments, treatment target, translational science The term mood disorders is used to describe psychiatric conditions presenting with changes in emotional states. Bipolar disorder (BD) and major depression disorder (MDD) are among the most studied mood disorders that cause significant functional impairment. 1,2 Although the etiology of mood disorders has not been completely elucidated, it has been proposed that both environmental and genetic factors may underlie their pathophysiology. 1,2 Regarding the contribution of genetic factors, the role of multiple genes showing small size effects is the most acceptable model. For the environmental conditions, several risk factors have been associated with increased risk of developing MDD and BD including, early adverse stress, psychological stressors, and drug abuse. 3–5 The combination of environmental and genetic factors may lead to intermediate phenotypes, such as altered brain gene expression and circuitry dysfunction, that affect mood disturbances. 6 These alterations may be associated with changes in different cellular pathways that culminate in inflammation, 7,8 decreased neuroplasticity, 9 increased oxidative stress, 10 and cell death. 11 The endo-lysosomal and autophagy pathway (ELAP) and the ubiquitin-proteasome system (UPS) play critical roles in maintaining cellular homeostasis by controlling the quality and trafficking of the proteins. Since protein quality is crucial for the pathways involved in mood disorders, recent discoveries have shed light on the role of ELAP and UPS in these disorders. The presence of misfolded proteins in specific brain regions are pathological hallmarks of neurodegenerative diseases (NDDs) including Alzheimer's disease (AD). 12 For this reason, the role of ELAP and UPS in NDDs is well recognized 13,14 and has offered a starting point for new possibilities for the treatment of these diseases. 15 Clinically, NDDs patients show psychiatric and behavioral alterations in addition to cognitive impairment. 16 Furthermore, a recent follow-up study showed that having a mental disorder (especially MDD and BD) can increase the risk of developing dementia later in life. 17 Shared clinical symptoms and the fact that mood disorders may increase the risk for NDDs suggest that common molecular mechanisms may underlie mental disorders. 16 Although the contribution of specific molecular pathways has been addressed, a subset of MDD patients does not respond to current pharmacological treatments available. 1 Furthermore, the diagnosis and management of MDD and BD suggest that patients may benefit from new treatment strategies. A better understanding of the mo -Abstract Truncated-
psychiatry,clinical neurology